NEW YORK, Feb. 4, 2014 /PRNewswire/ -- Attorney Advertising
-- Bronstein, Gewirtz & Grossman, LLC is investigating
potential claims on behalf of purchasers of the securities of
Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (NasdaqCM:
ORMP). Such investors are advised to contact Peretz Bronstein or his investor Relation's
coordinator Eitan Kimelman at
info@bgandg.com or 212-697-6484.
The investigation concerns whether Oramed and certain of its
officers and/or directors have violated federal securities laws.
On Monday, February 3, 2014, a
report was published on TheStreet.com website questioning the
integrity and robustness of the data presented by the Company
regarding its Oral Insulin Pill, with the report calling such data
"Completely Worthless".
On this news, shares of Oramed fell $5.32 or 24.08% to close at $16.77.
If you are aware of any facts relating to this investigation, or
purchased shares of Oramed you can assist this investigation by
contacting Peretz Bronstein or his
Investor Relations Coordinator Eitan
Kimelman of Bronstein, Gewirtz & Grossman, LLC at
212-697-6484 or via email info@bgandg.com. Those who inquire
by e-mail are encouraged to include their mailing address, email
and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com
SOURCE Bronstein, Gewirtz & Grossman, LLC